LAMEA Biosimilars Market

LAMEA Biosimilars Market Size, Share & Industry Trends Analysis Report By Application (Oncology Diseases, Blood Disorders, Chronic & Autoimmune Diseases and Others), By Type, By Country and Growth Forecast, 2022 - 2028

Report Id: KBV-10559 Publication Date: August-2022 Number of Pages: 98
Special Offering:
Industry Insights | Market Trends
Highest number of Tables | 24/7 Analyst Support

Market Report Description

The Latin America, Middle East and Africa Biosimilars Market would witness market growth of 29.4% CAGR during the forecast period (2022-2028).

Biosimilars act as a supplemental form of chemotherapy and thus play a significant part in the treatment of cancer. Therefore, the prevalence of various cancers is rising will increase the demand for biosimilars. The FDA defines a biosimilar as a biological product that is extremely similar to and essentially identical to one that has already received FDA approval.

The reference product and the biosimilars share many structural as well as functional characteristics. Modern manufacturing techniques are used to create these products in order to compare properties such as bioactivity, purity, & chemical identity between the target product and reference product. Small variations in stabilizers or buffers, which are clinically inactive components, are acceptable.

This is clear biologics that have improved the way in which cancer, autoimmune diseases, and genetic conditions are treated, improving the futures of numerous people. No compromises are made in the product's safety, quality, or efficacy due to the FDA's standards for drug approval. This is true whether the treatment is a biologic or a biosimilar. Regardless of the method of treatment, both cutting-edge approaches signal exciting new directions in the management of complex diseases like cancer.

Being one of the Middle East's most developed and diverse economies, the UAE has a strong healthcare infrastructure. The UAE government has placed a high priority on developing a first-rate healthcare infrastructure, which has helped the sector expand and develop over the past few years. Given that public spending accounts for more than two-thirds of all healthcare expenditures, the UAE government's support for the medical sector is one of the main growth drivers in the country. The government's plans to improve national capabilities to fight upcoming pandemics include efforts to develop vaccines & medicines as well as a new supply chain-focused strategy.

The Brazil market dominated the LAMEA Biosimilars Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1,076.7 million by 2028. The Argentina market is anticipated to grow at a CAGR of 30% during (2022 - 2028). Additionally, The UAE market would witness a CAGR of 29% during (2022 - 2028).

Based on Application, the market is segmented into Oncology Diseases, Blood Disorders, Chronic & Autoimmune Diseases and Others. Based on Type, the market is segmented into Monoclonal Antibodies, Granulocyte-Colony Stimulating Factor, Erythropoietin, Human Growth Hormone, Insulin and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

Free Valuable Insights: The Global Biosimilars Market is Predict to reach $59 Billion by 2028, at a CAGR of 24.4%

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., Biocon Limited, Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, Intas Pharmaceutical Ltd, Novartis AG (Sandoz), Merck & Co., Inc., Pfizer, Inc., Teva Pharmaceuticals Industries Ltd. and Fresenius SE & Co. KGaA

Scope of the Study

Market Segments Covered in the Report:

By Application

  • Oncology Diseases
  • Blood Disorders
  • Chronic & Autoimmune Diseases
  • Others

By Type

  • Monoclonal Antibodies
  • Granulocyte-Colony Stimulating Factor
  • Erythropoietin
  • Human Growth Hormone
  • Insulin
  • Others

By Country

  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

  • Amgen, Inc.
  • Biocon Limited
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • Intas Pharmaceutical Ltd
  • Novartis AG (Sandoz)
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • Fresenius SE & Co. KGaA
Need a report that reflects how COVID-19 has impacted this market and its growth? Download Free Sample Now


Call: +1(646) 600-5072


  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities

Unique Offerings Unique Offerings

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Support with 10% customization free after sale

Trusted by over
5000+ clients

Our team of dedicated experts can provide you with attractive expansion opportunities for your business.

Client Logo